A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian sarcoma group study

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 508-516

  Grignani, G ^a   Palmerini, E ^b   Dileo, P ^c   Asaftei, S D ^d   D'ambrosio, L ^a   Pignochino, Y ^a   Mercuri, M ^b   Picci, P ^b   Fagioli, F ^d   Casali, P G ^c   Ferrari, S ^b   Aglietta, M ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Bone neoplasms; MAPK; Osteosarcoma; Relapse; Sorafenib; Target therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; SORAFENIB;

ABDOMINAL CRAMP; ADJUVANT THERAPY; ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER GRADING; CANCER RELAPSE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; ITALY; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; OPEN STUDY; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BLEEDING; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 84856343533     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr151     Document Type: Article

References (45)

1. Raymond AK, Ayala AG, Kuutila S. Conventional osteosarcoma. In Fletcher CDM, Unni KK, Mertens F(eds), World Health Organization Classification of Tumours. Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002; 264-270.
2. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002; 20: 776-790.
3. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
4. Bacci G, Ferrari S, Bertoni F et al. Long-term out come for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18: 4016-4027.
5. Meyers PA, Schwartz L, Trailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-636.
6. Chou AJ, Kleinerman ES, Krailo MD et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma. Cancer 2009; 115: 5339-5348.
7. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
8. Kempf-Bielack B, Bielack SS, Jurgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
9. McGary EC, Weber K, Mills L et al. Inhibition of platelet-derived growth factormediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002; 8: 3584-3591.
10. Sulzbacher I, Birner P, Trieb K et al. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003; 16: 66-71.
11. Kubo T, Piperdi S, Rosenblum J et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129.
12. Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572-577.
13. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009; 9: 511-523.
14. Kolb EA, Kamara D, Zhang W et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010; 55: 67-75.
15. Skotlandi K, Manara MC, Nicoletti G et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16: 530-540.
16. Pignochino Y, Grignani G, Cavalloni G et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118-123.
17. Abdeen A, Chou AJ, Healey JH et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009; 115: 5243-5250.
18. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
19. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
20. Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
21. Abou-Alfa GK, Schwartz L, Ricci S et al.; Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
22. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis. Common terminology criteria for adverse events v3.0 (CTCAE) 2006; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (15 January 2011, date last accessed).
23. Hawkins DS, Conrad EU III, Butrynski JE et al. [F-18]-fluorodeoxy-D-glucosepositron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115: 3519-3525.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Caraceni A, Mendoza TR, Mencaglia E et al. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996; 65: 87-92.
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
27. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl 1): 122S-150S.
28. Navid F, Willert JK, McCarville MB et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113: 419-425.
29. Berger M, Grignani G, Ferrari S et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009; 115: 2980-2987.
30. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Bone Cancer version 3. 2010.; Fort Washington, PA. Published by the National Comprehensive Cancer Network online at the URL address: http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf (15 January 2011, date last accessed).
31. Benjamin RS, Debiec-Rychter M, Le Cesne A et al. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol 2009; 36: 302-311.
32. Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology 2010; 75: 1108-1113.
33. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
34. Le Cesne A, Van Glabbeke M, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27: 3969-3974.
35. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000; 92: 179-181.
36. Tuma RS. Sometimes size doesn't matter: revaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006; 98: 1272-1274.
37. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
38. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22: 4442-4445.
39. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
40. Leary SE, Billups CA, Watkins A et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. J Clin Oncol 2008; 26: (Abstr 10516). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31932 (15 January 2011, date last accessed).
41. Maki RG, D'Adamo RD, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
42. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2010; 152: 467-478.
43. Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 2010; 25: 683-691.
44. Díaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 2006; 42: 1491-1500.
45. Wan X, Mendoza A, Khanna C et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-2411